Dr. Reddy's Laboratories Ltd. Sponsored ADR Stock News

Dr. Reddy's Laboratories Limited (NYSE:RDY ) Q1 2026 Earnings Conference Call July 23, 2025 10:00 AM ET Company Participants Erez Israeli - CEO & Member of the Management Council Mannam Venkatanarasimham - CFO & Member of the Management Council Richa Periwal - Head of Investor Relations and Analytics Conference Call Participants Abdulkader Puranwala - ICICI Securities Limited, Research Division...

HYDERABAD, India--(BUSINESS WIRE)---- $RDY #ConsolidatedFinancialResults--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the quarter ended June 30, 2025.

Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 countries next year, the Indian drugmaker's CEO, Erez Israeli, said on Wednesday.

HYDERABAD, India & REYKJAVIK, Iceland--(BUSINESS WIRE)---- $RDY #Alvotech--Alvotech and Dr. Reddy's Enter into collaboration to co-develop biosimilar candidate to Keytruda® (pembrolizumab).

I reiterate my strong buy rating on Dr. Reddy's Laboratories due to its attractive valuation and underappreciated growth potential beyond Revlimid. Recent results exceeded expectations, with 20% YoY revenue growth driven by acquisitions and strong performance in generics, especially in Europe and India. While Revlimid's patent expiry poses a headwind, RDY's robust pipeline in biosimilars and GL...

Dr. Reddy's Laboratories Limited (NYSE:RDY ) Q4 2025 Earnings Conference Call May 9, 2025 10:00 AM ET Company Participants Richa Periwal - Head, IR and Analytics Erez Israeli - CEO M V Narasimham - CFO Conference Call Participants Neha Manpuria - Bank of America Kunal Dhamesha - Macquarie Group Madhav Marda - Fidelity Amey Chalke - JM Financial Bino Pathiparampil - Elara Capital Krishnendu Saha...

HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the quarter and year ended March 31, 2025.

The Trump administration's proposed tariffs on pharmaceuticals have caused significant market turmoil today, with major Pharma stocks plummeting globally. Despite pledges to increase U.S. manufacturing, companies like Eli Lilly and Novo Nordisk are suffering substantial share price declines. The feasibility of relocating drug manufacturing to the U.S. is highly questionable, potentially leading...